Deep Brain Stimulation–Withdrawal Syndrome in Parkinson’s Disease: Risk Factors and Pathophysiological Hypotheses of a Life-Threatening Emergency
Stéphan Grimaldi(Hôpital de la Timone), Tatiana Witjas(Hôpital de la Timone), Romain Carron(Inserm), Jean-Marie Régis(Aix-Marseille Université), Alexandre Eusébio(Aix-Marseille Université), Jean‐Philippe Azulay(Assistance Publique Hôpitaux de Marseille), Lionel Velly(Centre National de la Recherche Scientifique)
Cited by 23
Related Papers
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
|Nature Medicine|2000|515
Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial
|The Lancet|2018|395
Trial of Lixisenatide in Early Parkinson’s Disease
|New England Journal of Medicine|2024|302
Reliability of standard pupillometry practice in neurocritical care: an observational, double-blinded study
|Critical Care|2016|260
Management of severe traumatic brain injury (first 24 hours)
|Anaesthesia Critical Care & Pain Medicine|2017|238